Fig. 5From: WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy targetOverexpression of WT1 partially prevents WP1130-induced anti-leukemic activity. a The protein expression of WT1 was measured in THP1 and Kasumi-1 cells, which were transduced with control MSCV-NC or MSCV-WT1. b and c Apoptosis was measured by annexin V/PI staining in THP1 (b) and Kasumi-1 cells (c), which were transduced with control MSCV-NC or MSCV-WT1, followed by the treatment of WP1130 (5.0 µM) for 24 h. d and e Colonies were scored in THP1 and Kasumi-1 cells, which were transduced with MSCV-NC or MSCV-WT1 and then treated by WP1130 (5.0 µM) for 24 h. Shown are the representative pictures showing colonies (left) and statistical analysis of colonies scored (right). Bar represents 50 µmBack to article page